Answers are grounded in this paper and cite their sources.
CTLA4 blockade with tremelimumab diversifies the peripheral T-cell pool, representing a pharmacodynamic effect of how this class of antibodies modulates the human immune system.
No takes yet. Share an insight, caveat, or question.
Robert et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: